Terms: = Leukemia AND IL7R, P16871, IL-7R-alpha, CDW127, CD127, ENSG00000168685, 3575
190 results:
1. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Suske T; Sorger H; Manhart G; Ruge F; Prutsch N; Zimmerman MW; Eder T; Abdallah DI; Maurer B; Wagner C; Schönefeldt S; Spirk K; Pichler A; Pemovska T; Schweicker C; Pölöske D; Hubanic E; Jungherz D; Müller TA; Aung MMK; Orlova A; Pham HTT; Zimmel K; Krausgruber T; Bock C; Müller M; Dahlhoff M; Boersma A; Rülicke T; Fleck R; de Araujo ED; Gunning PT; Aittokallio T; Mustjoki S; Sanda T; Hartmann S; Grebien F; Hoermann G; Haferlach T; Staber PB; Neubauer HA; Look AT; Herling M; Moriggl R
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618957
[TBL] [Abstract] [Full Text] [Related]
2. Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection.
Lee CH; Hsu KW; Hsieh YY; Li WT; Long Y; Lin CY; Chen SH
Cells; 2024 Apr; 13(7):. PubMed ID: 38607055
[TBL] [Abstract] [Full Text] [Related]
3. CRISPR/Cas9-Based Disease Modeling and Functional Correction of Interleukin 7 Receptor Alpha Severe Combined Immunodeficiency in T-Lymphocytes and Hematopoietic Stem Cells.
Rai R; Steinberg Z; Romito M; Zinghirino F; Hu YT; White N; Naseem A; Thrasher AJ; Turchiano G; Cavazza A
Hum Gene Ther; 2024 Apr; 35(7-8):269-283. PubMed ID: 38251667
[TBL] [Abstract] [Full Text] [Related]
4. Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL.
Fregona V; Bayet M; Bouttier M; Largeaud L; Hamelle C; Jamrog LA; Prade N; Lagarde S; Hebrard S; Luquet I; Mansat-De Mas V; Nolla M; Pasquet M; Didier C; Khamlichi AA; Broccardo C; Delabesse É; Mancini SJC; Gerby B
J Exp Med; 2024 Jan; 221(1):. PubMed ID: 37930337
[TBL] [Abstract] [Full Text] [Related]
5. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Senapati J; Fiskus WC; Daver N; Wilson NR; Ravandi F; Garcia-Manero G; Kadia T; DiNardo CD; Jabbour E; Burger J; Short NJ; Alvarado Y; Jain N; Masarova L; Issa GC; Qiao W; Khoury JD; Pierce S; Miller D; Sasaki K; Konopleva M; Bhalla KN; Borthakur G; Pemmaraju N
Clin Cancer Res; 2023 Nov; 29(21):4352-4360. PubMed ID: 37585491
[TBL] [Abstract] [Full Text] [Related]
6. Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8
Shimizu K; Ueda S; Kawamura M; Aoshima H; Satoh M; Nakabayashi J; Fujii SI
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37400134
[TBL] [Abstract] [Full Text] [Related]
7. Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
Gao XN; Su YF; Li MY; Jing Y; Wang J; Xu L; Zhang LL; Wang A; Wang YZ; Zheng X; Li YF; Liu DH
Cancer Immunol Immunother; 2023 Aug; 72(8):2769-2782. PubMed ID: 37166484
[TBL] [Abstract] [Full Text] [Related]
8. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition.
Courtois L; Cabannes-Hamy A; Kim R; Delecourt M; Pinton A; Charbonnier G; Feroul M; Smith C; Tueur G; Pivert C; Balducci E; Simonin M; Angel LH; Spicuglia S; Boissel N; Andrieu GP; Asnafi V; Rousselot P; Lhermitte L
Blood; 2023 Jul; 142(2):158-171. PubMed ID: 37023368
[TBL] [Abstract] [Full Text] [Related]
9. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont H; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ
Blood; 2023 Jul; 142(3):274-289. PubMed ID: 36989489
[TBL] [Abstract] [Full Text] [Related]
10. INPP5K controls the dynamic structure and signaling of wild-type and mutated, leukemia-associated IL-7 receptors.
Moës B; Li H; Molina-Ortiz P; Radermecker C; Rosu A; Vande Catsyne CA; Sayyed SA; Fontela J; Duque M; Mostafa A; Azzi A; Barata JT; Merino R; Xu C; Desmet CJ; Schurmans S
Blood; 2023 Apr; 141(14):1708-1717. PubMed ID: 36599086
[TBL] [Abstract] [Full Text] [Related]
11. IL-7 and IL-7R in health and disease: An update through COVID times.
Fernandes MB; Barata JT
Adv Biol Regul; 2023 Jan; 87():100940. PubMed ID: 36503870
[TBL] [Abstract] [Full Text] [Related]
12. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract] [Full Text] [Related]
13. Low il7r Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid leukemia Patients With t(8;21).
Xu N; Sun K; Wang YZ; Chen WM; Wang J; Li LD; Wang X; Hao Y; Chang Y; Liu YR; Huang XJ; Qin YZ
Front Immunol; 2022; 13():909104. PubMed ID: 35874754
[TBL] [Abstract] [Full Text] [Related]
14. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Ho JNHG; Schmidt D; Lowinus T; Ryoo J; Dopfer EP; Gonzalo Núñez N; Costa-Pereira S; Toffalori C; Punta M; Fetsch V; Wertheimer T; Rittmann MC; Braun LM; Follo M; Briere C; Vinnakota JM; Langenbach M; Koppers F; Shoumariyeh K; Engel H; Rückert T; Märklin M; Holzmayer S; Illert AL; Magon F; Andrieux G; Duquesne S; Pfeifer D; Staniek J; Rizzi M; Miething C; Köhler N; Duyster J; Menssen HD; Boerries M; Buescher JM; Cabezas-Wallscheid N; Blazar BR; Apostolova P; Vago L; Pearce EL; Becher B; Zeiser R
Blood; 2022 Sep; 140(10):1167-1181. PubMed ID: 35853161
[TBL] [Abstract] [Full Text] [Related]
15. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract] [Full Text] [Related]
16. Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution.
Richter-Pechańska P; Kunz JB; Rausch T; Erarslan-Uysal B; Bornhauser B; Frismantas V; Assenov Y; Zimmermann M; Happich M; von Knebel-Doeberitz C; von Neuhoff N; Köhler R; Stanulla M; Schrappe M; Cario G; Escherich G; Kirschner-Schwabe R; Eckert C; Avigad S; Pfister SM; Muckenthaler MU; Bourquin JP; Korbel JO; Kulozik AE
Leukemia; 2022 Jul; 36(7):1759-1768. PubMed ID: 35585141
[TBL] [Abstract] [Full Text] [Related]
17. Mutant il7r collaborates with MYC to induce T-cell acute lymphoblastic leukemia.
Oliveira ML; Veloso A; Garcia EG; Iyer S; Pereira C; Barreto VM; Langenau DM; Barata JT
Leukemia; 2022 Jun; 36(6):1533-1540. PubMed ID: 35581375
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
Meyer LK; Delgado-Martin C; Sharp PP; Huang BJ; McMinn D; Vincent TL; Ryan T; Horton TM; Wood BL; Teachey DT; Taunton J; Kirk CJ; Hermiston ML
Br J Haematol; 2022 Jul; 198(1):137-141. PubMed ID: 35434798
[TBL] [Abstract] [Full Text] [Related]
19. Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic leukemia-The State-of-the-Art Knowledge and Future Prospects.
Kośmider K; Karska K; Kozakiewicz A; Lejman M; Zawitkowska J
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409154
[TBL] [Abstract] [Full Text] [Related]
20. Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.
Almeida ARM; Neto JL; Cachucho A; Euzébio M; Meng X; Kim R; Fernandes MB; Raposo B; Oliveira ML; Ribeiro D; Fragoso R; Zenatti PP; Soares T; de Matos MR; Corrêa JR; Duque M; Roberts KG; Gu Z; Qu C; Pereira C; Pyne S; Pyne NJ; Barreto VM; Bernard-Pierrot I; Clappier E; Mullighan CG; Grosso AR; Yunes JA; Barata JT
Nat Commun; 2021 Dec; 12(1):7268. PubMed ID: 34907175
[TBL] [Abstract] [Full Text] [Related]
[Next]
